Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company (KFSHI), shared a post on X:
“FLT3 Inhibitors choice in AML:
Midostaurin vs. Quizartinib
Midostaurin:
Targets FLT3-ITD & FLT3-TKD
QTc <500ms
Favored in males
maintenance post-chemotherapy
Quizartinib:
Targets FLT3-ITD only
QTc <450 ms
Favored in females, WBC ≥40, NPM1-mutated
maintenance post-alloTx.”
